glp 1 agonist weight loss GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH The GLP-1 Agonists and Obesity:

Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Compare every GLP-1 drug for weight loss, see clinical results, and find out which is right for you.

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)